Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)

Clinical trial NCT06975618 · RECRUITING

Trial details

NCT number: NCT06975618
Sponsor: Haihe Biopharma Co., Ltd.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

PIK3CA-Related Overgrowth Spectrum (PROS)PIK3CA-related Vascular Malformations (PRVM)

Start date: 2023-08-22
Primary completion: 2029-12-31
Enrollment: 141

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.